Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05356182
Other study ID # STUDY00005755
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 4, 2022
Est. completion date April 2024

Study information

Verified date March 2024
Source State University of New York at Buffalo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main idea of this study is that a low protein diet may alter the environment surrounding the tumor, enhancing the body's immune response leading to greater anticancer effects of treatment. This study intends to use a low-protein diet as a tool to enhance the immune response generated by immune check point inhibitor treatments.


Description:

This is a single center, randomized, open label study to assess the feasibility of a low-protein diet intervention in cancer patients who are receiving immunotherapies. Subjects will be randomized in a 1:1 ratio to either immunotherapy plus control diet arm (~20% protein content) or immunotherapy plus intervention low-protein diet arm (10% protein content).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically documented solid tumor malignancies which is amenable for immunotherapy treatment with immune checkpoint inhibitors (i.e. PD1, PD-L1, CTLA inhibitors) as single agents or in combination. - Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan of the chest, abdomen, and pelvis - Life expectancy of at least 6 months - Adults = 18 years of age - Adequate hematologic, renal, and liver function as evidenced by the following: - White blood cell (WBC) = 2,500 cells/µL - Absolute neutrophil count (ANC) = 1,000 cells/µL - Platelet Count = 100,000 cells/µL - Hemoglobin (HgB) = 9.0 g/dL - Creatinine = 2.0 mg/dL - Total bilirubin = 2 x upper limit of normal (ULN) - Aspartate aminotransaminase (AST, SGOT) = 2.5 x ULN - Alanine aminotransaminase (ALT, SGPT) = 2.5 x ULN Exclusion Criteria: - • Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher - Treatment with any of the following medications or interventions within 28 days of registration: - Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable. - High dose calcitriol [1,25(OH)2VitD] (i.e., > 7.0 µg/week) - A requirement for systemic immunosuppressive therapy for any reason - Any infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5°F or 38.1°C) within 1 week prior to registration - A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging - Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Diet
Control diet consisting of 20% protein, intervention diet consisting of 10% protein

Locations

Country Name City State
United States University at Buffalo / Great Lakes Cancer Care Buffalo New York

Sponsors (1)

Lead Sponsor Collaborator
State University of New York at Buffalo

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the feasibility of low-protein diet intervention in cancer patients receiving immunotherapies. Change in blood urea nitrogen (BUN) from baseline to post-intervention (following 3 cycles of treatment) will be measured to assess adherence of following the diet intervention. 4 Months
Primary To assess the feasibility of low-protein diet intervention in cancer patients receiving immunotherapies. Change in urine urea nitrogen (UUN) from baseline to post-intervention (following 3 cycles of treatment) will be measured to assess adherence of following the diet intervention. 4 Months
Secondary To assess whether low-protein diet intervention augments the immune response to immunotherapies in cancer patients receiving immunotherapies Includes isolation and characterization of antigen specific T cell clones 4 Months
Secondary To assess whether low-protein diet intervention augments the immune response to immunotherapies in cancer patients receiving immunotherapies Includes evaluation of antigen specific T cell populations by spectratyping T cell receptor expression 4 Months
Secondary To assess whether low-protein diet intervention augments the immune response to immunotherapies in cancer patients receiving immunotherapies Includes characterization of antigen response by cytokine and chemokine production 4 Months
Secondary To assess the enrollment rate (safety and tolerability) of the combination of immunotherapies and low-protein diet intervention Enrollment rate 4 Months
Secondary To assess the Drop-out rate (safety and tolerability) of the combination of immunotherapies and low-protein diet intervention Drop-out rate 4 Months
Secondary To assess the safety and tolerability of the combination of immunotherapies and low-protein diet intervention Compliance with diet measured by self-report of patient 4 Months
Secondary To obtain preliminary evidence of clinical efficacy of immunotherapies and low-protein diet compared to immunotherapies and control-diet using the RECIST v1.1 criteria Objective Response Rate (ORR) 4 Months
Secondary To obtain preliminary evidence of clinical efficacy of immunotherapies and low-protein diet compared to immunotherapies and control-diet using the RECIST v1.1 criteria Progression-Free Survival (PFS) 4 Months
Secondary To obtain preliminary evidence of clinical efficacy of immunotherapies and low-protein diet compared to immunotherapies and control-diet using the RECIST v1.1 criteria Overall Survival(OS) 4 Months
See also
  Status Clinical Trial Phase
Completed NCT02824042 - Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Phase 1
Completed NCT02253420 - COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients Phase 1
Completed NCT02357953 - Transpulmonary Thermodilution Using an Implented Central Venous Access Port N/A
Completed NCT02645357 - Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients N/A
Recruiting NCT04931329 - Onco-haematology Vigilance Card
Terminated NCT02138812 - Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel Phase 1
Terminated NCT02368951 - Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) Phase 1
Not yet recruiting NCT05423808 - Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients. N/A
Terminated NCT02439346 - Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel Phase 1
Recruiting NCT05385718 - Ezra Faster Scan Study
Completed NCT02457351 - Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study Phase 1
Completed NCT02906423 - Results From a Health System-wide Implementation of a Quality of Life Questionnaire N/A
Completed NCT01409135 - A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 Phase 1
Not yet recruiting NCT02327806 - The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance N/A
Completed NCT02639091 - Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Phase 1
Completed NCT02366949 - Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel Phase 1
Not yet recruiting NCT06097533 - Improvement of Quality of Life by Cannabinoids in Oncologic Patients Phase 2/Phase 3
Completed NCT02427490 - A Problem-Solving Intervention for Family Caregivers in Palliative Oncology N/A
Recruiting NCT05359848 - A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy N/A